Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 393

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer

Open access
Lee, Helen, Shields, Anthony F., Siegel, Barry A., Miller, Kathy D., Krop, Ian, Ma, Cynthia X., LoRusso, Patricia M., Munster, Pamela N., Campbell, Karen, Gaddy, Daniel F., Leonard, Shannon C., Geretti, Elena, Blocker, Stephanie J., Kirpotin, Dmitri B., Moyo, Victor, Wickham, Thomas J., Hendriks, Bart S.·2017·Clinical Cancer Research

Abstract

Purpose: Therapeutic nanoparticles are designed to deliver their drug payloads through enhanced permeability and retention (EPR) in solid tumors. The extent of EPR and its variability in human tumors is highly debated and has been proposed as an explanation for variable responses to therapeutic nanoparticles in clinical studies. Experimental Design: We assessed the EPR effect in patients using a 64Cu-labeled nanoparticle, 64Cu-MM-302 (64Cu-labeled HER2-targeted PEGylated liposomal doxorubicin), and imaging by PET/CT. Nineteen patients with HER2-positive metastatic breast cancer underwent 2 to 3 PET/CT scans postadministration of 64Cu-MM-302 as part of a clinical trial of MM-302 plus trastuzumab with and without cyclophosphamide (NCT01304797). Results: Significant background uptake of 64Cu-MM-302 was observed in liver and spleen. Tumor accumulation of 64Cu-MM-302 at 24 to 48 hours varied 35-fold (0.52–18.5 %ID/kg), including deposition in bone and brain lesions, and was independent of systemic plasma exposure. Computational analysis quantified rates of deposition and washout, indicating peak liposome deposition at 24 to 48 hours. Patients were classified on the basis of 64Cu-MM-302 lesion deposition using a cut-off point that is comparable with a response threshold in preclinical studies. In a retrospective exploratory analysis of patient outcomes relating to drug levels in tumor lesions, high 64Cu-MM-302 deposition was associated with more favorable treatment outcomes (HR = 0.42). Conclusions: These findings provide important evidence and quantification of the EPR effect in human metastatic tumors and support imaging nanoparticle deposition in tumors as a potential means to identify patients well suited for treatment with therapeutic nanoparticles. Clin Cancer Res; 23(15); 4190–202. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-3193

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 393

Metadata

Authors
Lee, H., Shields, A. F., Siegel, B. A., Miller, K. D., Krop, I., Ma, C. X., LoRusso, P. M., Munster, P. N., Campbell, K., Gaddy, D. F., Leonard, S. C., Geretti, E., Blocker, S. J., Kirpotin, D. B., Moyo, V., Wickham, T. J., & Hendriks, B. S.
Venue
Clinical Cancer Research
Published
2017-08-01
Volume
23
Issue
15
Pages
4190-4202
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2597588035
Cited by
393
References
44
FWCI
12.92
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-3193
The paper
Lee, H., Shields, A. F., Siegel, B. A., Miller, K. D., Krop, I., Ma, C. X., LoRusso, P. M., Munster, P. N., Campbell, K., Gaddy, D. F., Leonard, S. C., Geretti, E., Blocker, S. J., Kirpotin, D. B., Moyo, V., Wickham, T. J., & Hendriks, B. S. (2017). 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-3193

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.